Prime/Magellan Rx earns top score on the Disability Equality Index

Prime Therapeutics/Magellan Rx Management (Prime/Magellan Rx) recently received a top score of 100 on the Disability Equality Index^®, a comprehensive benchmarking tool for organizations to measure disability workplace inclusion and to assess company performance across the business world. This comes after Prime/Magellan Rx earned a score of 90 in 2022 and 100 in 2023.

“Prime/Magellan Rx is honored to receive a top score on the Disability Equality Index, as it highlights our commitment to disability inclusion and broader diversity, equity and inclusion initiatives,” said Zabrina Watkins, diversity, equity and inclusion director at Prime/Magellan Rx. “We know that more than 1.3 billon people live with a disability worldwide and want to ensure our workplace is inclusive to everyone. While we are proud of our score of 100, we know that it doesn’t convey perfection, and we are always looking for ways to make our practices more inclusive.”

Top-scoring businesses — those scoring 80 or higher — are recognized as a “Best Place to Work for Disability Inclusion.” In 2024 alone, 542 corporations participated in the index.

The 2024 Disability Equality Index measured:

• Culture and leadership
• Enterprise-wide access
• Employment practices (benefits, recruitment, employment, education, retention, advancement and accommodations)
• Community engagement
• Supplier diversity
• Responsible procurement

The Disability Equality Index was launched in 2015 and is acknowledged as the most robust disability inclusion assessment tool. It was originally modeled off the template established by the Corporate Equality Index that highlights LGBTQ+-inclusive workplace policies, on which Prime/Magellan Rx also scored 100.